Can B's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Can B (CANB) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Can B vs Its Competitors
- TTM: Trailing 12-month revenue of 1M vs 1,222M combined for its competitors (0.1% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-92.7% annualized vs trailing 12 months), vs decelerating (-23.4%) for its tracked peer group.
- Growth: Can B generated -96.4% revenue growth year over year in Q3 2024, vs 16.4% for its competitors combined.
- Profitability: Its -21,367.6% net margin compares with -11.7% for the peer group.
- Peer revenue share: Can B accounted for 0.0% of combined revenue among its tracked peer group, down from 0.2% a year earlier.
- Peer differentiation: Revenue per employee of $0.04M compares with $0.31M for the peer group (0.1x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
CANB Sales vs. its Competitors, Q3 2024
Can B reported revenue contraction of 96.36 % year on year in Q3 2024, below its competitors' combined revenue growth of 16.40 %.
With a net margin of -21,367.56 %, Can B reported lower profitability than its competitors (-11.68 %).
Can B generated 0.01 % of the combined sales of its peer group, down from 0.21 % a year earlier.
API endpoints for this dataset
Can B vs. its Competitors, Q3 2024
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Can B reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Can B and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Can B Corp | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (3) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Can B's competitor groups requires a Commercial License.
For context: the Pharmacy Services & Retail Drugstore industry grew revenue 6.4% year over year, combined, vs -96.4% for Can B. Can B's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.
Can B's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Can B Corp | - | No | No | No |
| Competitors combined (3) | ||||
| High-Confidence Competitors (5) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
CANB Stock Performance relative to its Competitors
CANB Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Cronos Group Inc | 282.9% | Outperformed |
| 2 | Aurora Cannabis Inc | 282.9% | Outperformed |
| 3 | Tilray Brands Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Can B's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Can B's Comment on Competition and Industry Peers
Publicly Traded Peers of Can B Corp
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Can B Corp |
1.16 | 0.84 |
 Cronos Group Inc |
1,267.71 | 259.21 |
 Tilray Brands Inc |
324.02 | 962.31 |
 Aurora Cannabis Inc |
- | 369.53 |
| SUBTOTAL | 1,592.89 | 1,591.89 |
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Can B Corp versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Can B's Competitors Named by the Company
Competitive relationships identified from Can B reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Gaia Herbs | Company report | 85% |
| CV Sciences | Company report | 85% |
| Seven Chakras, LLC | Company report | 85% |
| Aurora Cannabis | Company report | 85% |
| GW Pharmaceuticals | Company report | 85% |
| Elixinol LLC | Company report | 85% |
| Charlotte’s Web | Company report | 85% |
| Medical Marijuana | Company report | 85% |
| Tilray Brands Inc | Company report | 85% |
| Cronos Group Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Can B's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Can B's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Tilray Brands Inc | Beverage Alcohol Business 39.47 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Can B's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Can B Corp | 1 | 44,231 | -697,813 |
| Cronos Group Inc | 1,268 | 424,938 | 129,843 |
| Tilray Brands Inc | 324 | 267,681 | -41,672 |
| Aurora Cannabis Inc | - | 369,528 | -104,148 |
| PEERS TOTAL | 1,592 | 305,678 | -33,575 |
Can B's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Cronos Group Inc | Other countries 8.98 % |
| Tilray Brands Inc | EMEA 56.59 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Can B's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Pharmacy Services & Retail Drugstore industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (34 companies). See the full Pharmacy Services & Retail Drugstore industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | -40.85 % | 24.65 % (avg) | -65.5 pp |
| Operating Margin | -13.88 % | industry median | -9.1 pp |
| EBITDA Margin | - | -1.51 % (avg) | - |
| Capital Intensity (Capex / Revenue) | 0.00 % | 2.44 % (avg) | -2.4 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Can B's Valuation vs Competitive Position
Valuation multiples vs the Pharmacy Services & Retail Drugstore industry average (34 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Pharmacy Services & Retail Drugstore industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 22.2x | - |
| EV / EBITDA | - | 12.2x | - |
| P/B | -0.1x | 3.6x | -3.7x |
| Return on Equity | - | industry aggregate | - |
| Return on Invested Capital | - | 7.40 % (avg) | - |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Can B's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Revenue Growth | 444.70 % | 244.82 % | -25.84 % | 169.28 % | 45.22 % | -67.75 % |
| Operating Margin | -510.88 % | -198.83 % | -255.86 % | - | - | - |
| Return on Invested Capital | -134.68 % | -41.06 % | -46.40 % | -137.78 % | -136.99 % | 300.84 % |
| P/E | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Can B's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 0.00 % vs industry average 2.44 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Can B's dedicated Suppliers and Customers pages, not here.
Can B's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Operating margin 9.1 points below the industry median.
- Latest-quarter revenue run-rate is decelerating (-92.7% annualized vs trailing 12 months).
Opportunities
No rule matched.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-23.4% annualized).
Methodology: see Methodology: SWOT Analysis.
Can B's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Can B Corp | 0.00 | 0.34 | - |
| Cronos Group Inc | 15.24 | 19.71 | - |
| Tilray Brands Inc | 0.69 | 2.27 | 0.22 |
| Aurora Cannabis Inc | 0.97 | 5.94 | - |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Can B's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Can B Corp | Q3 2024 | -96.4 % | - |
| Cronos Group Inc | Q2 2026 | +269.5 % | - |
| Tilray Brands Inc | Q3 2026 | +22.8 % | - |
| Aurora Cannabis Inc | Q1 2026 | +49.7 % | - |
| PEERS TOTAL | +53.0 % | - |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Can B's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Can B Corp | Q3 2024 | -66.3 % | - |
| Cronos Group Inc | Q2 2026 | +66.5 % | -80.8 % |
| Tilray Brands Inc | Q3 2026 | +18.2 % | - |
| Aurora Cannabis Inc | Q1 2026 | - | - |
Can B's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Can B Corp | - | - | - |
| Cronos Group Inc | 6.70% | 6.90% | 7.25% |
| Tilray Brands Inc | - | - | - |
| Aurora Cannabis Inc | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Can B's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Can B Corp | - | 1.39 |
| Cronos Group Inc | 17.79 | 4.89 |
| Tilray Brands Inc | - | 0.34 |
| Aurora Cannabis Inc | - | - |
| PEERS AVERAGE | - | 1.00 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.